www.cytoreason.com
Open in
urlscan Pro
192.116.109.25
Public Scan
Submitted URL: http://www.cytoreason.com/
Effective URL: https://www.cytoreason.com/
Submission: On October 11 via api from US — Scanned from DE
Effective URL: https://www.cytoreason.com/
Submission: On October 11 via api from US — Scanned from DE
Form analysis
0 forms found in the DOMText Content
This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy. We won't track your information when you visit our site. But in order to comply with your preferences, we'll have to use just one tiny cookie so that you're not asked to make this choice again. Accept Decline Skip to content Open toolbar Accessibility Tools * Increase Text * Decrease Text * Grayscale * High Contrast * Negative Contrast * Light Background * Links Underline * Readable Font * Reset Skip to content LATEST NEWS: CYTOREASON AND PFIZER SIGN $110M COLLABORATION DEAL! read all about it * Technology * Solutions * Resources * Press Releases * Media Coverage * Scientific Publications * Case studies * Blog * Company * Careers Menu * Technology * Solutions * Resources * Press Releases * Media Coverage * Scientific Publications * Case studies * Blog * Company * Careers Contact us * Home * Technology * Solutions * Resources * Press Release * Media Coverage * Scientific Publications * Case studies * Blog * Company * Careers * Contact us Menu * Home * Technology * Solutions * Resources * Press Release * Media Coverage * Scientific Publications * Case studies * Blog * Company * Careers * Contact us * Home * Technology * Solutions * Resources * Press Release * Media Coverage * Scientific Publications * Case studies * Blog * Company * Careers * Contact us Menu * Home * Technology * Solutions * Resources * Press Release * Media Coverage * Scientific Publications * Case studies * Blog * Company * Careers * Contact us BRING DATA TO LIFE From trial and error to predictable medicine See how disease models work BRING DATA TO LIFE From trial and error to predictable medicine See how disease models work LATEST NEWS: CYTOREASON AND PFIZER SIGN $110M COLLABORATION DEAL! read all about it THE CYTOREASON DISEASE MODEL Think of it as the most comprehensive model of human diseases. Modeling and comparing treatments and patient groups so you get a clear map of disease and drug mechanisms. get inside MANAGE YOUR DRUG PORTFOLIO Prioritize all of your programs, compare your treatments to competing treatments, and your drugs across patient populations. MANAGE YOUR DRUG PORTFOLIO Prioritize all of your programs, compare your treatments to competing treatments, and your drugs across patient populations. SEE THE FOREST AND THE TREES Give your scientist a deep profile of your drug, and your executive a bird’s-eye view of your entire portfolio. One platform for all users. SEE THE FOREST AND THE TREES Give your scientist a deep profile of your drug, and your executive a bird’s-eye view of your entire portfolio. One platform for all users. LISTEN TO LIVING DATA Base your decisions on the latest human data as your disease models are updated. Use live results to make accurate predictions. LISTEN TO LIVING DATA Base your decisions on the latest human data as your disease models are updated. Use live results to make accurate predictions. KNOW THE RISK AHEAD Connect molecular mechanisms to your drug’s performance and compare to other drugs in the market. Follow early signals and gain long-term confidence. KNOW THE RISK AHEAD Connect molecular mechanisms to your drug’s performance and compare to other drugs in the market. Follow early signals and gain long-term confidence. Get inside the model IN THE NEWS Media Coverage September 22nd, 2022 CYTOREASON, PFIZER INK $110M, 5-YEAR EXTENSION OF AI-POWERED DRUG DEVELOPMENT DEAL https://www.fiercebiotech.com/medtech/cytoreason-pfizer-ink-110m-five-year-extension-ai-powered-drug-development-deal read more Media Coverage March 24th, 2022 POOLBEG PHARMA SIGNS FIRST OF ITS KIND AI DEAL WITH CYTOREASON read more Press Release February 10th, 2022 CYTOREASON AND PFIZER EXTEND COLLABORATION TO LEVERAGE MACHINE LEARNING IN DRUG DEVELOPMENT read more more news '' THE DIFFERENCE BETWEEN USING CYTOREASON TECHNOLOGY AND NOT USING IT, IS THE DIFFERENCE BETWEEN ENGINEERING AND ART. '' MIKE VINCENT SVP Immunology & Inflammation HOME * Technology * Solutions * Company * Careers * Contact us Menu * Technology * Solutions * Company * Careers * Contact us RESOURCES * Press Releases * Media Coverage * Scientific Publications * Case studies * Blog Menu * Press Releases * Media Coverage * Scientific Publications * Case studies * Blog * cytoreason@cytoreason.com Accessibility | Terms of Use | Privacy Policy | All rights reserved CytoReason LTD © 2022 | Designed and Developed by: Webnoise We are using cookies to give you the best experience on our website. You can find out more about which cookies we are using or switch them off in settings. Accept Close GDPR Cookie Settings * Privacy Overview * Strictly Necessary Cookies Powered by GDPR Cookie Compliance Privacy Overview This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Strictly Necessary Cookies Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings. Enable or Disable Cookies If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again. Enable All Save Settings